MADISON, Wis.–Voximetry Inc., a Healthtech software company with unique technology for personalized Radiopharmaceutical Therapy (RPT) has been awarded a substantial grant from the U.S. National Institutes of Health (NIH)’s National Cancer Institute (NCI) to further advance development of its proprietary software for RPT dose assessment and treatment planning.
According to Voximetry CEO, Dr. Sue Wallace, “We truly appreciate the NIH/NCI SBIR program’s vision to support scientific excellence and technological innovation through the investment of Federal research funds in critical American healthcare priorities helping to build a strong national economy. This additional supplemental grant will accelerate our work to provide an automated tool that offers dosimetry guidance to clinicians and thereby personalized care for individual patients.”
The $206,000 Phase II Small Business Innovation Research (SBIR) supplemental grant from the NIH/NCI will fund commercial development of Voximetry’s Torch™ software*.
“After treatment, our users will visualize how much therapeutic dose was delivered to the targeted disease sites, as well as to healthy tissue and critical organs. And they will get full Monte Carlo dose calculation accuracy in seconds,” said Dr. Joe Grudzinski, Voximetry Chief Innovation Officer.
*510(k) pending. Torch™ is under FDA review and is NOT Available for sale or clinical use